New York, USA – August 3, 2022 – Since the approval of Soliris, an anti-C5 antibody, in 2007, the field of complement drug discovery has received significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications, according to the Research and Markets.
The complement system is part of the innate immune system and can be brought into action by antibodies in the adaptive immune system. It plays a key role in innate defense against pathogens and assisting antibodies in assaulting incoming infections. Components in the complement system, such as C5, C3, and C1s, have become hot targets in therapeutics development.
The complement system can be stimulated in three pathways depending on the activation triggers: classical, lectin, and alternative pathways. Among these, the classical pathway acts as the link between effectors of innate and adaptive immunities. Currently, at least 21 serum proteins have been verified as components of the classical pathway.
Complement C3, as the central component of the complement system’s intricate protein network, is linked to a variety of immunomodulatory systems and biological processes that alter human physiology and pathophysiology, making it a focus for complement-targeted therapeutic intervention.
Creative Biolabs has developed the C3-target complement therapeutic services for various conditions such as systemic lupus erythematosus (SLE), endotoxin shock, and membranoproliferative glomerulonephritis (MPGN). At Creative Biolabs, C3 products, including C3 antibodies, C3 proteins, and C3 assay kits, are also available.
A full range of therapeutic antibodies, inhibitors, and soluble complement regulators development services for the classical pathway targets are also offered at Creative Biolabs.
In addition, following the trend of the pharmaceutical industry, the development of antibody-based therapeutics has grown rapidly. Based on advanced technology and experience, Creative Biolabs is now capable of offering comprehensive antibody-based therapeutic development services.
Complement component 5 (C5) plays a critical role in inflammatory and cell killing processes and has proven to be associated with several diseases. Creative Biolabs provides antibody development services against the C5 target and other antibody-based therapeutic services, such as CD20 antibody development, CD46 (MCP) antibody development, CD55 (DAF) antibody development, and CD59 (MIRL) antibody development.
More information about complement therapeutic services at Creative Biolabs can be found at https://www.creative-biolabs.com/complement-therapeutics.
About Creative Biolabs
As a global biotech company with more than a decade of exploration and expansion, Creative Biolabs offers comprehensive one-stop services for complement therapeutics and fully customizable experimental design to meet various needs.
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Country: United States